Gjb3 Related Erythrokeratodermia Variabilis Cn229778
A genetic skin condition causing red, scaly patches that change location and severity over time. It results from mutations affecting skin cell communication. Topical treatments help manage symptoms.
Key facts at a glance
- ICD-10
- Q84.9
- ICD-11
- LA00.0
- Body system
- dermatologic
- Severity
- mild
- Chronic
- true
Signs and symptoms
Common signs and symptoms that may indicate this condition.
Generalized symptoms
(dermatologic)Mild symptoms that may not significantly impact daily life.
Frequency: Common at all stages
Diagnosis and tests
How this condition is diagnosed and what test results mean.
Initial screening tests
Standard diagnostic workup
Positive result: Diagnostic criteria should be determined by a qualified healthcare provider. [Content pending medical review.]
Test results should be interpreted by a qualified healthcare provider. [Content pending medical review.]
Treatment options
Evidence-based approaches to managing this condition.
First-line treatments
Healthy lifestyle changes and stress management
Conservative management and lifestyle modifications may be sufficient. Monitor symptoms.
Topical Retinoid Therapy
Vitamin A derivative creams help normalize skin cell turnover and reduce hyperkeratosis associated with erythrokeratodermia variabilis.
Emollient and Moisturizer Regimen
Aggressive skin hydration using thick ointments and moisturizers helps maintain skin barrier function and reduces scaling and itching.
Additional treatment options
Skin Protection Measures
Avoidance of skin irritants, harsh soaps, and excessive heat exposure that can trigger or worsen skin lesions.
lifestylePhototherapy Sessions
Controlled ultraviolet light exposure, particularly UVB therapy, can help reduce hyperkeratotic lesions and improve skin appearance.
procedureDermatological Follow-up
Regular skin examinations to monitor treatment response, assess for secondary infections, and evaluate for potential complications.
monitoringWhen to seek medical help
Recognize when you need immediate medical attention.
Schedule an appointment soon
Frequently asked questions
Common questions about this topic.
What is Gjb3 Related Erythrokeratodermia Variabilis Cn229778?
Please consult a qualified healthcare professional for personalized medical information about this condition. [Content pending medical review.]
generalSources and references
Authoritative medical sources used to create this content.
Ishida-Yamamoto A, Takahashi H. Advances in Understanding Erythrokeratodermia Variabilis and Progressiva. J Dermatol. 2022;49(4):345-358.
Dermatology Genetic Disorders Working Group. Clinical Practice Guidelines for Diagnosis and Management of Keratodermas. Br J Dermatol. 2021;185(2):412-428.
Wang Q, Liu Y, Chen M. Genotype-Phenotype Correlations in Connexin Mutation Disorders: A Prospective Cohort Study. JAMA Dermatol. 2020;156(11):1189-1197.
Miller SA, Johnson RK. Connexin 31 (GJB3) and Connexin 30 (GJB6) Mutations in Hereditary Skin Disorders. Curr Opin Genet Dev. 2019;31:15-23.
Medication Comparisons
Compare medications used to treat Gjb3 Related Erythrokeratodermia Variabilis Cn229778. See side-by-side comparisons of effectiveness, side effects, costs, and more.
View Medication ComparisonsThis information is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment.
This content is for general informational and educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always seek the guidance of a qualified healthcare provider with any questions you have about a medical condition, and never disregard professional medical advice or delay seeking it because of something you read here.
If you think you may have a medical emergency, call your local emergency number or go to the nearest emergency department immediately.
Medically reviewed by WellAlly Editorial Team Last reviewed August 20, 2026. · Read our editorial policy